Clinical development of cardio-renal drugs
Cardiokine was a specialty pharmaceutical company founded around the licensing of Lixivaptan from Wyeth Pharmaceuticals in 2004. Lixivaptan is a sodium sparing diuretic that had completed multiple Phase I and Phase II trials.
CEO Amber Salzman
Advent invested in the Series B in 2006. The Company was sold to Cornerstone Therapeutics in 2012.
Cornerstone Therapeutics Acquires Cardiokine
Press Release. January 04, 2012 07:30 ET Cornerstone Therapeutics Acquires Cardiokine CARY, NC--(Marketwire - Jan 4, 2012) - Cornerstone Therapeutics (NASDAQ: CRTX) •Cornerstone acquires worldwide rights to investigational therapy…Read More